Cargando…

Constitutive activation of the EGFR–STAT1 axis increases proliferation of meningioma tumor cells

BACKGROUND: Meningiomas are the most frequent primary brain tumors of the central nervous system. The standard of treatment is surgery and radiotherapy, but effective pharmacological options are not available yet. The well-characterized genetic background stratifies these tumors in several subgroups...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferluga, Sara, Baiz, Daniele, Hilton, David A, Adams, Claire L, Ercolano, Emanuela, Dunn, Jemma, Bassiri, Kayleigh, Kurian, Kathreena M, Hanemann, Clemens O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212880/ https://www.ncbi.nlm.nih.gov/pubmed/32642677 http://dx.doi.org/10.1093/noajnl/vdaa008

Ejemplares similares

GATA-4, a potential novel therapeutic target for high-grade meningioma, regulates miR-497, a potential novel circulating biomarker for high-grade meningioma
por: Negroni, Caterina, et al.
Publicado: (2020)

A Rapid Robust Method for Subgrouping Non-NF2 Meningiomas According to Genotype and Detection of Lower Levels of M2 Macrophages in AKT1 E17K Mutated Tumours
por: Adams, Claire L., et al.
Publicado: (2020)

Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas
por: Sofela, Agbolahan A., et al.
Publicado: (2021)

Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target
por: Bassiri, Kayleigh, et al.
Publicado: (2017)

Proteomic analysis discovers the differential expression of novel proteins and phosphoproteins in meningioma including NEK9, HK2 and SET and deregulation of RNA metabolism
por: Dunn, Jemma, et al.
Publicado: (2018)

The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma
por: Lyons Rimmer, Jade, et al.
Publicado: (2020)

Epigenetic dysregulation in meningiomas
por: Wedemeyer, Michelle A, et al.
Publicado: (2022)

Tumor-associated macrophage infiltration in meningioma
por: Proctor, Dustin T, et al.
Publicado: (2019)

Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma
por: Dunn, Jemma, et al.
Publicado: (2020)

EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo
por: Jensen, Katharine V, et al.
Publicado: (2020)

Identification of shared genomic aberrations between angiomatous and microcystic meningiomas
por: Kuroi, Yasuhiro, et al.
Publicado: (2019)

The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma
por: Horbinski, Craig, et al.
Publicado: (2021)

EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma
por: Ding, Jie, et al.
Publicado: (2022)

Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Pleiotropic MLLT10 variation confers risk of meningioma and estrogen-mediated cancers
por: Walsh, Kyle M, et al.
Publicado: (2022)

Genetic variations in EGF and EGFR and glioblastoma outcome
por: Sjöström, Sara, et al.
Publicado: (2010)

Genome-wide association analysis identifies a meningioma risk locus at 11p15.5
por: Claus, Elizabeth B, et al.
Publicado: (2018)

Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment
por: Portet, Sylvain, et al.
Publicado: (2019)

H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort
por: Behling, Felix, et al.
Publicado: (2020)

Defining EGFR amplification status for clinical trial inclusion
por: French, Pim J, et al.
Publicado: (2019)

The CREB-binding protein inhibitor ICG-001: a promising therapeutic strategy in sporadic meningioma with NF2 mutations
por: Deng, Jiaojiao, et al.
Publicado: (2020)

A non-hierarchical organization of tumorigenic NG2 cells in glioblastoma promoted by EGFR
por: Al-Mayhani, Talal F, et al.
Publicado: (2019)

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
por: Boyle, D L, et al.
Publicado: (2015)

Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin
por: Gan, Hui K, et al.
Publicado: (2021)

Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway
por: González-Alvaro, I, et al.
Publicado: (2008)

EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand
por: Hoogstrate, Youri, et al.
Publicado: (2019)

Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors
por: Gao, W, et al.
Publicado: (2016)

Multi-OMICS analyses unveil STAT1 as a potential modifier gene in mevalonate kinase deficiency
por: Carapito, Raphael, et al.
Publicado: (2018)

Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts
por: Porath, Kendra A, et al.
Publicado: (2022)

Longitudinal analysis of serum-derived extracellular vesicle RNA to monitor dacomitinib treatment response in EGFR-amplified recurrent glioblastoma patients
por: Yekula, Anudeep, et al.
Publicado: (2023)

STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma
por: Zhang, Liang, et al.
Publicado: (2022)

IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis
por: Anderson, Amy E, et al.
Publicado: (2016)

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
por: Padfield, Emily, et al.
Publicado: (2015)

The STAT4 SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-γ production in T cells from patients with SLE
por: Hagberg, Niklas, et al.
Publicado: (2018)

Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3–ABCB1 Signaling in Hepatocellular Carcinoma
por: Hu, Beiyuan, et al.
Publicado: (2022)

A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease
por: Pratt, Arthur G, et al.
Publicado: (2012)

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells
por: Agarwal, S, et al.
Publicado: (2009)

Single-cell transcriptomic analyses provide insights into the cellular origins and drivers of brain metastasis from lung adenocarcinoma
por: Wang, Zihao, et al.
Publicado: (2023)

GBMdeconvoluteR accurately infers proportions of neoplastic and immune cell populations from bulk glioblastoma transcriptomics data
por: Ajaib, Shoaib, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qprms2uijf64p6mq1hod95nmsp